/
Oncology
Advanced Malignancies
44
Pipeline Programs↗
28
Active Trials↗
56
Companies Involved↗
Advanced Malignancies is a moderately active landscape with 44 programs across 56 companies. The most active players are BeOne Medicines, BeiGene, Pfizer. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 115
Phase 210
Phase 315
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
29 of 42 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 98% of 44 pipeline programs.
Analysis
Trial Status
193
clinical trials
Completed101 · 52%
Terminated43 · 22%
Recruiting18 · 9%
Unknown status10 · 5%
Withdrawn8 · 4%
Active, not recruiting7 · 4%
Other6 · 3%
Clinical Trials
Trial Activity
193 trials
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)